81 related articles for article (PubMed ID: 38650005)
1. Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma.
Long AW; Xu H; Santich BH; Guo H; Hoseini SS; de Stanchina E; Cheung NV
J Hematol Oncol; 2024 Apr; 17(1):20. PubMed ID: 38650005
[TBL] [Abstract][Full Text] [Related]
2. Identification of immunotherapy and radioimmunotherapy targets on desmoplastic small round cell tumors.
Espinosa-Cotton M; Guo HF; Tickoo SK; Cheung NV
Front Oncol; 2023; 13():1104693. PubMed ID: 37091153
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors.
Rosewell Shaw A; Porter CE; Yip T; Mah WC; McKenna MK; Dysthe M; Jung Y; Parihar R; Brenner MK; Suzuki M
Commun Biol; 2021 Mar; 4(1):368. PubMed ID: 33742099
[TBL] [Abstract][Full Text] [Related]
4. Structural and functional characterization of IgG- and non-IgG-based T-cell-engaging bispecific antibodies.
Mohan N; Ayinde S; Peng H; Dutta S; Shen Y; Falkowski VM; Biel TG; Ju T; Wu WJ
Front Immunol; 2024; 15():1376096. PubMed ID: 38863707
[TBL] [Abstract][Full Text] [Related]
5. Format-tuning of in vivo-launched bispecific T cell engager enhances efficacy against renal cell carcinoma.
O'Connell RP; Liaw K; Wellhausen N; Chuckran CA; Bhojnagarwala PS; Bordoloi D; Park D; Shupin N; Kulp D; June CH; Weiner D
J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38834201
[TBL] [Abstract][Full Text] [Related]
6. T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors.
Middelburg J; Sluijter M; Schaap G; Göynük B; Lloyd K; Ovcinnikovs V; Zom GG; Marijnissen RJ; Groeneveldt C; Griffioen L; Sandker GGW; Heskamp S; van der Burg SH; Arakelian T; Ossendorp F; Arens R; Schuurman J; Kemper K; van Hall T
Nat Commun; 2024 Jan; 15(1):48. PubMed ID: 38167722
[TBL] [Abstract][Full Text] [Related]
7. Reduced Tumor Volume and Increased Necrosis of Human Breast Tumor Xenograft in Mice Pretreated by a Cocktail of Three Specific Anti-HER2 scFvs.
Nejatollahi F; Nadimi E; Noorafshan A; Moazen S; Alizadeh AM; Khalighfard S; Sahebkar A
Curr Protein Pept Sci; 2024; 25(5):409-418. PubMed ID: 38018211
[TBL] [Abstract][Full Text] [Related]
8. Targeting both GD2 and B7-H3 using bispecific antibody improves tumor selectivity for GD2-positive tumors.
Rosenkrans ZT; Erbe AK; Clemons NB; Feils AS; Medina-Guevara Y; Jeffery JJ; Barnhart TE; Engle JW; Sondel PM; Hernandez R
bioRxiv; 2024 May; ():. PubMed ID: 38853889
[TBL] [Abstract][Full Text] [Related]
9. Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell-engaging bispecific antibody targeting human claudin 6.
Stadler CR; Ellinghaus U; Fischer L; Bähr-Mahmud H; Rao M; Lindemann C; Chaturvedi A; Scharf C; Biermann I; Hebich B; Malz A; Beresin G; Falck G; Häcker A; Houben A; Erdeljan M; Wolf K; Kullmann M; Chang P; Türeci Ö; Şahin U
Sci Transl Med; 2024 May; 16(748):eadl2720. PubMed ID: 38776391
[TBL] [Abstract][Full Text] [Related]
10. A Bispecific Modeling Framework Enables the Prediction of Efficacy, Toxicity, and Optimal Molecular Design of Bispecific Antibodies Targeting MerTK.
Li R; Dere E; Kwong M; Fei M; Dave R; Masih S; Wang J; McNamara E; Huang H; Liang WC; Schutt L; Kamath AV; Ovacik MA
AAPS J; 2024 Jan; 26(1):11. PubMed ID: 38167740
[TBL] [Abstract][Full Text] [Related]
11. Small-molecule-mediated control of the anti-tumour activity and off-tumour toxicity of a supramolecular bispecific T cell engager.
Gong N; Han X; Xue L; Billingsley MM; Huang X; El-Mayta R; Qin J; Sheppard NC; June CH; Mitchell MJ
Nat Biomed Eng; 2024 May; 8(5):513-528. PubMed ID: 38378820
[TBL] [Abstract][Full Text] [Related]
12. Geometric Antibody Engineering Reveals the Spatial Factor on the Efficacy of Bispecific T Cell Engagers.
Zhang Y; Yang Z; Saimi D; Shen X; Ye J; Yu B; Pefaur N; Scheer JM; Nixon AE; Chen Z
ACS Chem Biol; 2024 Apr; 19(4):916-925. PubMed ID: 38491942
[TBL] [Abstract][Full Text] [Related]
13. Mechanistic computational modeling of monospecific and bispecific antibodies targeting interleukin-6/8 receptors.
Ray CMP; Yang H; Spangler JB; Mac Gabhann F
PLoS Comput Biol; 2024 Jun; 20(6):e1012157. PubMed ID: 38848446
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic computational modeling of monospecific and bispecific antibodies targeting interleukin-6/8 receptors.
Ray CM; Yang H; Spangler JB; Mac Gabhann F
bioRxiv; 2023 Dec; ():. PubMed ID: 38187701
[TBL] [Abstract][Full Text] [Related]
15. BiSpec Pairwise AI: guiding the selection of bispecific antibody target combinations with pairwise learning and GPT augmentation.
Zhang X; Wang H; Sun C
J Cancer Res Clin Oncol; 2024 May; 150(5):237. PubMed ID: 38713378
[TBL] [Abstract][Full Text] [Related]
16. Bispecific antibodies: Potential immunotherapies for HIV treatment.
Fabozzi G; Pegu A; Koup RA; Petrovas C
Methods; 2019 Feb; 154():118-124. PubMed ID: 30352254
[TBL] [Abstract][Full Text] [Related]
17. T cell-redirecting antibody for treatment of solid tumors via targeting mesothelin.
Liu JJ; Pan ZD; Yue YL; Wang SS; Chen J; Jiang H; Zhang BH; Wu MY; Yuan YS; Bian YL; Yin HY; Wang L; Li JY; Gilly J; Xie YQ; Zhu JW
Acta Pharmacol Sin; 2024 Jun; ():. PubMed ID: 38858494
[TBL] [Abstract][Full Text] [Related]
18. Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy.
Qin X; Ning W; Liu H; Liu X; Luo W; Xia N
Acta Pharm Sin B; 2024 Jun; 14(6):2361-2377. PubMed ID: 38828136
[TBL] [Abstract][Full Text] [Related]
19. Patient derived cancer organoids model the response to HER2-CD3 bispecific antibody (BsAbHER2) generated from hydroxyapatite gene delivery system.
Liu Y; Wang C; Chen G; Chen J; Chen W; Lei K; Li J; Pan Y; Li Y; Zhao J; Li B; Tang D; Zeng L
Cancer Lett; 2024 Jun; ():217043. PubMed ID: 38876386
[TBL] [Abstract][Full Text] [Related]
20. Bispecific antibody drug conjugates: Making 1+1>2.
Gu Y; Wang Z; Wang Y
Acta Pharm Sin B; 2024 May; 14(5):1965-1986. PubMed ID: 38799638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
